The FDA has approved an expanded indication for the gammaCore device to include prevention of migraine.
Biohaven announced positive topline results from a pivotal phase 2/3 study evaluating rimegepant for the preventive treatment of episodic and chronic migraine in adults.
The presence of migraine and increasing headache pain intensity are associated with higher rates of anxiety, depression, inflammation, and sleep conditions, among other disorders.
Biohaven announced that rimegepant is now available for the acute treatment of migraine with or without aura in adults.
Compared with people without migraine, people with migraine and migraine with medication overuse headache often have deficits in metacognition.
A single-center study showed that intranasal ketamine effectively reduced pain in children with migraine from hospital admission to discharge.
Phase 2 clinical trials investigating lasmiditan reported higher incidence and severity of TEAEs, compared with the phase 3 studies.
Treatment with humanized monoclonal antibody galcanezumab for up to 1 year was safe and tolerable for episodic and chronic migraine prophylaxis.
The FDA has accepted for review the New Drug Application (NDA) for Qtrypta™ (M207) (zolmitriptan intracutaneous microneedle system; Zosano Pharma) for the acute treatment of migraine.
Plasma glucose levels are increased in patients with migraine with and without aura during spontaneous migraine attack compared with the interictal state.